• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国加快 COVID-19 疫苗国家许可上市进程。

Accelerated national lot release on COVID-19 vaccines in Republic of Korea.

机构信息

National Institute of Food & Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Republic of Korea; School of Pharmacy, Chungbuk National University, Cheongju, Republic of Korea.

National Institute of Food & Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Republic of Korea.

出版信息

Biologicals. 2022 Jun;77:24-27. doi: 10.1016/j.biologicals.2022.05.002. Epub 2022 Jun 2.

DOI:10.1016/j.biologicals.2022.05.002
PMID:35680495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9160014/
Abstract

Independent quality testing of samples from vaccine lots is part of quality assurance, especially to ensure the consistency of production lot by lot. Effective national lot release system that ensures the quality of each lot of vaccine before it is on the market is important because vaccines are intended to healthy people. In order to respond more quickly to public health crises such as the COVID-19 pandemic, the MFDS implements accelerated national lot release for rapid vaccination in Republic of Korea. For the accelerated system, improvement has been made in terms of timing of application for lot release and required documents. In addition, the processing period has been shortened and sampling method and test items have been streamlined. A thorough preparation for accelerated lot release has been developed by establishing test methods for a new platform in advance. As a result, a total of 43.88 million doses have been released within eight days on average. The accelerated lot release system has contributed significantly to rapid COVID-19 vaccination in Korea.

摘要

疫苗批次的独立质量检测是质量保证的一部分,特别是为了确保每批生产的一致性。建立有效的国家批放行体系,确保每批疫苗在上市前的质量,这一点很重要,因为疫苗是为健康人群设计的。为了更迅速地应对 COVID-19 大流行等公共卫生危机,韩国食品医药品安全处(MFDS)在韩国实施了加速国家批放行,以实现快速接种。对于加速系统,在批放行申请时间和所需文件方面进行了改进。此外,处理周期已经缩短,抽样方法和测试项目也得到了简化。通过预先建立新平台的测试方法,为加速批放行做了充分准备。结果,平均在 8 天内总共放行 4388 万剂疫苗。加速批放行系统为韩国 COVID-19 的快速疫苗接种做出了重大贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/af69c5639422/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/580f0d6c8277/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/d45e836d543e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/af69c5639422/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/580f0d6c8277/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/d45e836d543e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1a36/9160014/af69c5639422/gr3_lrg.jpg

相似文献

1
Accelerated national lot release on COVID-19 vaccines in Republic of Korea.韩国加快 COVID-19 疫苗国家许可上市进程。
Biologicals. 2022 Jun;77:24-27. doi: 10.1016/j.biologicals.2022.05.002. Epub 2022 Jun 2.
2
Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform.韩国新冠疫苗质量控制与国家批签发的考量要点:聚焦病毒载体平台
Osong Public Health Res Perspect. 2022 Feb;13(1):4-14. doi: 10.24171/j.phrp.2021.0311. Epub 2022 Feb 8.
3
Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea.制定大流行 COVID-19 疫苗分配框架:韩国的一项改良德尔菲共识研究。
J Korean Med Sci. 2021 Jun 14;36(23):e166. doi: 10.3346/jkms.2021.36.e166.
4
Six Pivotal Lessons Learned in South Korea for Whole-of-Government Approach to Successful COVID-19 Vaccine Rollout in Planetary Health.在行星健康领域,韩国采取的政府整体措施在成功推出 COVID-19 疫苗方面汲取的六大关键经验。
OMICS. 2022 Oct;26(10):567-579. doi: 10.1089/omi.2022.0064. Epub 2022 Sep 16.
5
Herd immunity: challenges and the way forward in Korea.群体免疫:韩国面临的挑战与前进道路。
Epidemiol Health. 2021;43:e2021054. doi: 10.4178/epih.e2021054. Epub 2021 Aug 18.
6
National prevalence and socioeconomic factors associated with the acceptance of COVID-19 vaccines in South Korea: a large-scale representative study in 2021.2021 年韩国大规模代表性研究:与 COVID-19 疫苗接种接受度相关的全国流行率和社会经济因素。
Eur Rev Med Pharmacol Sci. 2023 Sep;27(18):8943-8951. doi: 10.26355/eurrev_202309_33815.
7
Dynamics of the COVID-19 epidemic in the post-vaccination period in Korea: a rapid assessment.韩国接种疫苗后时期 COVID-19 疫情动态:快速评估。
Epidemiol Health. 2021;43:e2021040. doi: 10.4178/epih.e2021040. Epub 2021 May 27.
8
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
9
[Batch testing as an essential pillar of the supply of safe and effective vaccines].[批量检测作为安全有效疫苗供应的重要支柱]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Dec;65(12):1244-1250. doi: 10.1007/s00103-022-03611-1. Epub 2022 Oct 20.
10
Herbal medicine use in Republic of Korea to alleviate side effects of COVID-19 vaccines: A cross-sectional study.韩国草药医学的使用缓解 COVID-19 疫苗的副作用:一项横断面研究。
J Integr Med. 2023 Jul;21(4):361-368. doi: 10.1016/j.joim.2023.06.002. Epub 2023 Jun 8.

引用本文的文献

1
Development of an identity test for COVID-19 mRNA vaccines using SARS-CoV-2 NAT standard.利用严重急性呼吸综合征冠状病毒2核酸检测标准开发新冠mRNA疫苗身份验证测试。
Biosaf Health. 2025 Jul 16;7(4):224-227. doi: 10.1016/j.bsheal.2025.07.007. eCollection 2025 Aug.
2
Prophylactic and therapeutic vaccine development: advancements and challenges.预防性和治疗性疫苗的研发:进展与挑战。
Mol Biomed. 2024 Nov 11;5(1):57. doi: 10.1186/s43556-024-00222-x.
3
Report on the seventh meeting of national control laboratories for vaccines and biologicals of the WHO Western Pacific and South-East Asia member states.

本文引用的文献

1
COVID-19 vaccines: progress and understanding on quality control and evaluation.2019冠状病毒病疫苗:质量控制与评估的进展及认识
Signal Transduct Target Ther. 2021 May 18;6(1):199. doi: 10.1038/s41392-021-00621-4.
2
COVID-19 Vaccine Frontrunners and Their Nanotechnology Design.COVID-19 疫苗领跑者及其纳米技术设计。
ACS Nano. 2020 Oct 27;14(10):12522-12537. doi: 10.1021/acsnano.0c07197. Epub 2020 Oct 9.
3
Study on the Procedure for Lot Release of Vaccines in Japan.日本疫苗批签发程序研究
世界卫生组织西太平洋和东南亚区域会员国国家疫苗和生物制品控制实验室第七次会议报告。
Biologicals. 2023 Nov;84:101712. doi: 10.1016/j.biologicals.2023.101712. Epub 2023 Oct 3.
Jpn J Infect Dis. 2019 May 23;72(3):133-141. doi: 10.7883/yoken.JJID.2018.446. Epub 2018 Nov 30.